- Home
- SOPH vs ALT Comparison
SOPH vs ALT Comparison
Compare SOPH & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | ALT |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 415.3M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SOPH | ALT |
|---|---|---|
| Price | $4.89 | $3.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.00 | ★ $17.67 |
| AVG Volume (30 Days) | 92.4K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $2.58 | $2.87 |
| 52 Week High | $5.70 | $7.73 |
Technical Indicators
Market Signals| Indicator | SOPH | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 43.03 |
| Support Level | $4.54 | $2.91 |
| Resistance Level | $5.31 | $4.25 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 46.88 | 54.17 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.